Starpharma Holdings Limited announced the commencement in the U.S. of a trial to assess the safety and acceptability of SPL7013 Gel (VivaGel(TM)) in sexually active young women.
The Microbicide Trials Network (MTN) is leading the study, funded by the U.S. National Institutes of Health (NIH), in which VivaGel(TM) will be tested for the first time in sexually active young women to determine its safety, acceptability and ease of use. VivaGel(TM) is being developed as a vaginal microbicide for the prevention of HIV and genital herpes.
The expanded safety study is being conducted at the University of South Florida in Tampa, Florida, and the University of Puerto Rico in San Juan, Puerto Rico, through a collaboration between the MTN (an HIV/AIDS clinical trials network established by the National Institute of Allergy and Infectious Diseases, NIH), the Adolescent Medicine Trials Network for HIV/AIDS Interventions (of the National Institute of Child Health and Human Development, NIH), and Starpharma.
Nearly 50 percent of people infected with HIV/AIDS today are women and most of them become infected through sexual intercourse with male partners. Women under the age of 25 are particularly at risk of infection.
"We have already conducted clinical trials on the safety of VivaGel(TM) in sexually inactive women and men, but this is the first time the product will be used in sexually active young women, one of our target populations. This study, in addition to the usual safety data, will collect valuable information regarding the product's use and acceptability in the consumer setting," said Dr Jackie Fairley, Chief Executive Officer of Starpharma.
"The data from this trial will provide information of value to the development of VivaGel(TM) for all indications, including preventing the spread of genital herpes," added Dr Fairley.
The study will enroll 40 sexually active, HIV-negative women aged 18 tPage: 1 2 Related medicine news :1
. Results Of Human Trials Of Hungarian Bird-Flu Vaccine Expected Today2
. Vaccine For Dengue Fever On Trial In Asia-Pacific3
. DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope4
. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment5
. Sex, Race Influence Lung Cancer Trial Participation6
. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand7
. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection8
. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care9
. China Begins Human Trials For HIV/AIDS Drug10
. Patients Should Be Entitled to "Humane Compensation" if Drug Trials Go Wrong11
. HIV/AIDS Vaccine Trial To Be Initiated Soon